Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,301 to 2,320 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Novartis MenACWY Vaccine vs Licensed Meningococcal Vaccine: serious adverse events | 23 of 2,649 5 of 875 | 0.3 points -0.5 to 0.8 | 3,524 | NCT00450437 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults |
| Intervention vs Control: Number of Subjects Who Discussed Disease Risk With Primary Care Provider | 905 of 1,673 841 of 1,847 | 8.6 points 5.3 to 11.8 | 3,520 | NCT01468675 Health Information Technology (HIT) Enhanced Family History Documentation and Management in Primary Care |
| Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Myocardial Reinfarction | 126 of 1,755 149 of 1,749 | -1.3 points -3.1 to 0.4 | 3,504 | NCT02981407 Myocardial Ischemia and Transfusion |
| Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Composite of All-cause Mortality, Nonfatal Myocardial Reinfarction, Ischemia Driven Unscheduled Coronary Revascularization, or Readmission to the Hospital for Ischemic Cardiac Diagnosis | 305 of 1,755 342 of 1,749 | -2.2 points -4.7 to 0.4 | 3,504 | NCT02981407 Myocardial Ischemia and Transfusion |
| Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Pulmonary Embolism or Deep Venous Thrombosis | 34 of 1,755 26 of 1,749 | 0.5 points -0.4 to 1.3 | 3,504 | NCT02981407 Myocardial Ischemia and Transfusion |
| Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Ischemia Driven Unscheduled Coronary Revascularization | 39 of 1,755 43 of 1,749 | -0.2 points -1.3 to 0.8 | 3,504 | NCT02981407 Myocardial Ischemia and Transfusion |
| Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Composite of All-cause Mortality,Nonfatal Myocardial Reinfarction, or Unstable Angina | 300 of 1,755 338 of 1,749 | -2.2 points -4.8 to 0.3 | 3,504 | NCT02981407 Myocardial Ischemia and Transfusion |
| Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: All-cause Mortality | 146 of 1,755 173 of 1,749 | -1.6 points -3.5 to 0.3 | 3,504 | NCT02981407 Myocardial Ischemia and Transfusion |
| Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Number of Participants With All-cause Mortality or Nonfatal Myocardial Reinfarction | 255 of 1,755 295 of 1,749 | -2.3 points -4.7 to 0.1 | 3,504 | NCT02981407 Myocardial Ischemia and Transfusion |
| Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Stroke | 26 of 1,755 30 of 1,749 | -0.2 points -1.1 to 0.6 | 3,504 | NCT02981407 Myocardial Ischemia and Transfusion |
| Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Heart Failure | 111 of 1,755 102 of 1,749 | 0.5 points -1.1 to 2.1 | 3,504 | NCT02981407 Myocardial Ischemia and Transfusion |
| Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: deaths from any cause | 353 of 1,755 376 of 1,749 | -1.4 points -4.1 to 1.3 | 3,504 | NCT02981407 Myocardial Ischemia and Transfusion |
| Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: serious adverse events | 699 of 1,755 723 of 1,749 | -1.5 points -4.8 to 1.7 | 3,504 | NCT02981407 Myocardial Ischemia and Transfusion |
| Group 1: Ad26.RSV.preF and RSV preF Protein vs Group 2: Placebo: Number of Participants With Unsolicited AEs up to 28 Days After Vaccination | 554 of 2,330 206 of 1,165 | 6.1 points 3.2 to 8.8 | 3,495 | NCT04908683 A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older |
| Part B (Blinded): Monovalent, Month 6 Hybrid Immunity vs Part B (Blinded): Bivalent, Month 6 Hybrid Immunity: Part B: Number of Participants With a First Occurrence of CDC-based COVID-19 Starting 14 Days After Month 6 Dose Until End of Follow up in RM6 Cohort Who Have Month 6 Hybrid Immunity Between Month 6 Monovalent and Bivalent Boost Groups | 140 of 1,732 123 of 1,759 | 1.1 points -0.7 to 2.9 | 3,491 | NCT05168813 Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern |
| Losmapimod 7.5 mg BID vs Placebo: Number of Participants Re-hospitalized Within 30 Days of Discharge | 213 of 1,731 210 of 1,758 | 0.4 points -1.8 to 2.5 | 3,489 | NCT02145468 A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60) |
| Losmapimod 7.5 mg BID vs Placebo: deaths from any cause | 57 of 1,724 68 of 1,752 | -0.6 points -1.8 to 0.7 | 3,476 | NCT02145468 A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60) |
| Losmapimod 7.5 mg BID vs Placebo: serious adverse events | 363 of 1,724 323 of 1,752 | 2.6 points -0.0 to 5.3 | 3,476 | NCT02145468 A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60) |
| Arm B: Anastrozol - 1 mg Per Day for 5 Years vs Arm A: Anastrozol - 1 mg Per Day for 2 Years: deaths from any cause | 207 of 1,738 207 of 1,732 | -0.0 points -2.2 to 2.1 | 3,470 | NCT00295620 Secondary Adjuvant Long Term Study With Arimidex |
| Right Ventricle Lead-Related Complications vs Summary of System and/or Procedure Related Complications Not Related to the RV Lead.: deaths from any cause | 323 of 1,735 323 of 1,735 | 0.0 points -2.6 to 2.6 | 3,470 | NCT02235545 Optisure Lead Post Approval Study |
Code
curl "https://conductscience.org/api/comparisons/v1?page=116"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=116
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00450437-sae",
"title": "Novartis MenACWY Vaccine vs Licensed Meningococcal Vaccine: serious adverse events",
"summary": "23 of 2649 against 5 of 875; risk difference 0.3 points, 95% interval -0.5 to 0.8; NCT00450437, A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults",
"record": "/library/comparisons/NCT00450437-sae",
"nct_id": "NCT00450437",
"kind": "serious-adverse-events",
"participants": 3524,
"risk_difference": {
"value": 0.002968235992018551,
"lower": -0.005155356574925693,
"upper": 0.008381216061161132
},
"group_1": "23 of 2,649",
"group_2": "5 of 875",
"difference": "0.3 points",
"interval": "-0.5 to 0.8",
"trial_title": "A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults"
},
{
"id": "NCT01468675-ccb91540",
"title": "Intervention vs Control: Number of Subjects Who Discussed Disease Risk With Primary Care Provider",
"summary": "905 of 1673 against 841 of 1847; risk difference 8.6 points, 95% interval 5.3 to 11.8; NCT01468675, Health Information Technology (HIT) Enhanced Family History Documentation and Management in Primary Care",
"record": "/library/comparisons/NCT01468675-ccb91540",
"nct_id": "NCT01468675",
"kind": "outcome",
"participants": 3520,
"risk_difference": {
"value": 0.08561143884964267,
"lower": 0.052560917961035236,
"upper": 0.11839824357657026
},
"group_1": "905 of 1,673",
"group_2": "841 of 1,847",
"difference": "8.6 points",
"interval": "5.3 to 11.8",
"trial_title": "Health Information Technology (HIT) Enhanced Family History Documentation and Management in Primary Care"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=117",
"request_id": "HVwtKAWDTADkQwhb"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant